Navigation Links
Daiichi Sankyo Launches LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Date:7/19/2011

TOKYO, July 19, 2011 /PRNewswire/ -- Building on its cardiovascular portfolio, Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), is proud to announce the launch of LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) in Japan. This announcement follows the first marketing approval for edoxaban 15 mg and 30 mg tablets by the Japanese Ministry of Health, Labor and Welfare in April 2011 (1), and marks the first time edoxaban is commercially available to patients in any global market.

Edoxaban is a once-daily, oral anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Results from clinical studies supported the approval of edoxaban for the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.

"Today's launch of edoxaban marks the global debut of the medication, which is an exciting breakthrough for patients who require VTE prevention after major orthopedic surgery," said Joji Nakayama, president and CEO of Daiichi Sankyo. "Edoxaban demonstrates solid efficacy in clinical trials (2, 3) in this population of patients. Its predictable pharmacokinetic and pharmacodynamic profile allows for a convenient, once-daily dosing."

The global clinical development program for edoxaban is focused on several indications, including stroke prevention in atrial fibrillation (AF) patients, and treatment and prevention of recurrent VTE. Edoxaban is currently being assessed in the Phase III ENGAGE AF-TIMI 48 study (4), an ongoing, multinational, randomized, double-blind trial evaluating the efficacy and safety of edoxaban in preventing stroke and systemic embolic events in patients with AF. More than 21,000 patients with AF in 46 countries are being examined, making this the largest trial in this indication to date. In addition, Daiichi Sankyo is currently enrolling patients in its HOKUSAI VTE study (5)
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
6. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
7. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
10. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
11. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 This report analyzes the worldwide markets ... following Product Segments: SPECT Systems (Includes SPECT and SPECT/CT systems), ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2013 through 2020. Also, ...
(Date:9/16/2014)... 2014 3SBio Inc., ("3SBio") a leading ... focusing on researching, developing, manufacturing and marketing ... into an exclusive license agreement with JenKem Technology ... marketing in Mainland China of PEG-irinotecan, a long-acting ... is over-expressed in many solid tumors, including colorectal, ...
(Date:9/16/2014)... The Pulmonary Fibrosis Foundation (PFF) announced today ... 1,100 patients and families suffering from pulmonary fibrosis (PF) ... the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis ... to seek patient input in order to better understand ... "We applaud the FDA for focusing its attention on ...
Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 263SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical applications, has entered into a new, ... SANTE (SES) of Algiers, Algeria for the distribution ...
... BME (BioMedical Enterprises, Inc.), a developer and manufacturer ... United States launch of Speed™. It is the first ... to orthopaedic and podiatric surgeons. BME, the ... its extensive knowledge in memory metal implant design to ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Algeria 2Misonix Announces New Distribution Agreement for Algeria 3
(Date:9/16/2014)... 2014 Keep that sexy decolletage as you ... neck. , "The Face Whisperer Neck & Decollete Cream ... Heshelow, founder of Sublime Beauty®. "It contains rich ingredients to ... and arnica." , A special ingredient is Argireline, known as ... rich anti-aging cream comes in an airless pump bottle, and ...
(Date:9/16/2014)... Holganix, an elite member of the ... in the country, produces an organic Bionutritional product that ... naturally decreasing disease and insect damage though significant root ... will hold its third annual Bionutritional Summit at the ... from 1:00 P.M. through 6:00 P.M., the day before ...
(Date:9/16/2014)... 2014; San Francisco) In a healthcare climate ... against potential benefit, a Yale study has found ... radiation procedures on elderly women with early-stage breast ... at the 56th annual conference of the American ... 131: Evaluating National Practice in Radiotherapy for Elderly ...
(Date:9/16/2014)... Pulmonary Hypertension Association Travels to San Diego for ... Patients and Families to Help Fight Rare Lung Disease , ... pulmonary hypertension association that works to find ways to prevent ... lungs that affects the functioning of the heart and can ... only 2.8 years. , What:, PHA On The ...
(Date:9/16/2014)... -- Modern forensic techniques are shedding light on a ... Richard III, the last English monarch to die in ... remains, using whole-body CT scans and micro-CT imaging of ... injuries he suffered at the Battle of Bosworth Field, ... modern forensics revealed that two skull injuries could have ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Holganix Holds 3rd Annual Bionutrional Summit in Louisville, Kentucky 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Modern Forensics Provides Clues to Death of Richard III 2
... MEDai, Inc., headquartered in,Orlando, FL, a leading ... longstanding Pinpoint Quality(TM) client, Sharp,HealthCare of San ... Baldrige National,Quality Award., The Baldrige award ... quality and organizational performance excellence. Congress,established the ...
... of Medical Administration Lauds and ... ... /Xinhua-PRNewswire-FirstCall/ -- Linkwell,Corporation (OTC Bulletin Board: LWLL), a leading ... announced,today that its Chairman and CEO, Mr. Xuelian Bian ...
... in PSAs for personal health record awareness, ... Information,Management Association (AHIMA) launched the "It,s HI Time, ... on the,importance of improving the management of their ... This campaign encourages Americans -- especially caregivers, maturing,adults, ...
... It,s a fact of life that everyone,has problems. But, ... others. Those with mental illness, addiction, or,HIV/AIDS often face ... don,t understand. Dealing with illness is often a lonely,heartbreaking ... those who battle such things have an online hub ...
... 28 In a reversal of what has,become the ... interactive training coupled with two hours of live phone,tech ... EZM Web,customers., EZM Web tracks and controls maintenance ... plus inventory control via the Web. It is accessible,from ...
... (Nasdaq: IACI ),announced today that it has ... (http://www.healthcentral.com ), a leading collection of,health and ... of,the deal have not been disclosed., The ... 30 owned and,operated condition-specific and healthy living websites ...
Cached Medicine News:Health News:MEDai Client Named Recipient of 2007 Malcolm Baldrige National Quality Award 2Health News:MEDai Client Named Recipient of 2007 Malcolm Baldrige National Quality Award 3Health News:Linkwell Chairman & CEO Addresses the Association of Chinese Nosocomial Infections Professional Committee 2Health News:Linkwell Chairman & CEO Addresses the Association of Chinese Nosocomial Infections Professional Committee 3Health News:AHIMA Launches National PHR Consumer Awareness Campaign 2Health News:WebTribes Offers Online Home for Those with Illnesses 2Health News:Maintenance Software Company Bucks Trend, Offers Unlimited No-Charge Product Tech Support 2Health News:IAC Acquires a Minority Stake in The HealthCentral Network 2Health News:IAC Acquires a Minority Stake in The HealthCentral Network 3
Used in the peritoneal cavity to remove large volumes of thick exudate....
100cc silicone evacuator...
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Medicine Products: